Waiting for 3rd Quarter Results…. Third quarter results should be out by next Friday (latest) and looking back at last year’s 3rd quarter results, here are a few takeaways:
- If the company wants to restore any lost confidence from shareholders, they should at the vey least address to some extent (without necessarily infringing partnership confidentiality agreements due to partners being private firms) the progress regarding the development of the various blood-based assays for different diseases with BC Neuroimmunology as well as serological assays for SARS-CoV-2 they announced last year at this time.
- This also goes for the AD vaccine they are working on with VIDO-InterVac since they began back in September 2020.
I found it odd that the company deemed it necessary to hire an external firm in order to sway shareholders to go along with management’s proposed consolidation scheme. Are they that concerned they won’t get the votes from shareholders?
Perhaps if they were a little more transparent with their progress over the course of the last 6-8 months this process could have been avoided.
Or perhaps this all happened/happens for a reason and we’ll hopefully know soon enough if it goes our (shareholder) way or not.